Market Overview The Liraglutide and Semaglutide Market was valued at USD 15.19 billion in 2024 and is projected to reach USD 35.01 billion by 2032, expanding at a CAGR of 11% during the forecast period
These include (1) decreased availability of amino acids (malnutrition, maldigestion, and malabsorption), (2) catabolic states (hyperthyroidism, Cushings syndrome, burns, postsurgery recovery), (3) protein-losing states (nephrotic syndrome and protein-losing enteropathy), (4) actions of cytokines (decrease in transport proteins such as albumin, transferrin, and lipoproteins, but increase in inflammatory response modifiers such as 1 -antitrypsin, ceruloplasmin, and 2 -macroglobulin), (5) action of hormones (such as growth hormone, cortisol, estrogen, androgens, and thyroid hormones) to increase or decrease production of specific proteins, and (6) congenital deficiency states (Wilsons disease and 1 -antitrypsin deficiency)
Importantly, the researchers did not identify any relationship between these serious adverse events and the use of retatrutide
Campbell L, Howie F, Arthur JR, Nicol F, Beckett G
Remember, semaglutide is most effective when combined with a reduced-calorie diet and increased physical activity, forming a comprehensive approach to health
If you need comprehensive type 2 diabetes care, an endocrinologist or diabetes-focused telehealth service may serve you better